Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$201.57 USD

201.57
1,465,839

+1.10 (0.55%)

Updated Nov 5, 2024 12:53 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Tirthankar Chakraborty headshot

50-Day Rally Spells Good Times for Wall Street: 5 Solid Buys

With Wall Street notching a 50-day rally amid signs of the economic slump bottoming out and history hinting further gains, investing in stocks that are poised to gain in the near term seems judicious.

Shuvra Shankar Dey headshot

4 Safe Dividend Bets Amid Coronavirus-Induced Uncertainty

Although a bulk of companies across diverse sectors have suspended dividends, a handful are sailing through this tough economic time and maintaining dividend payouts.

Top Ranked Value Stocks to Buy for June 4th

Here are four stocks with buy rank and strong value characteristics for investors to consider today, June 4th

Bristol Myers' Zeposia Meet Goals in Ulcerative Colitis Study

Bristol Myers' (BMY) late-stage study of Zeposia in patients with moderate-to-severe ulcerative colitis meets both its main goals.

Is AbbVie (ABBV) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Increased Earnings Estimates Seen for AbbVie (ABBV): Can It Move Higher?

AbbVie (ABBV) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

AbbVie (ABBV) closed at $91.04 in the latest trading session, marking a +0.37% move from the prior day.

Myovant Eyes Relugolix Combo Approval for Uterine Fibroids

Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix combination regimen as a treatment for heavy menstrual bleeding associated with uterine fibroids.

AbbVie Seeks US and EU Nods for Rinvoq for Psoriatic Arthritis

AbbVie (ABBV) files applications to the FDA and the EMA seeking approval for a new indication of Rinvoq, active psoriatic arthritis. The drug is already marketed to treat rheumatoid arthritis.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - June 02, 2020

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

The Zacks Analyst Blog Highlights: Tencent, Abbvie and Reckitt Benckiser

The Zacks Analyst Blog Highlights: Tencent, Abbvie and Reckitt Benckiser

Benjamin Rains headshot

3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity

Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...

AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding

The FDA approves AbbVie's (ABBV) Oriahnn oral capsule for checking heavy menstrual bleeding related to uterine fibroids in pre-menopausal women. It will be sold in US markets by June-end.

John Blank headshot

Positives and Negatives: Global Week Ahead

The growing divergence between an increasingly dire economic landscape and a roaring U.S. stock market will be on display on Friday when May non-farm payroll employment data is reported.

Lilly's Cyramza Gets FDA Approval for First-Line Lung Cancer

FDA approves Lilly's (LLY) Cyramza as a combination regimen for metastatic EGFR-mutated non-small cell lung cancer. Cyramza is now approved for six indications to treat four different types of cancers.

Why Is AbbVie (ABBV) Up 12.7% Since Last Earnings Report?

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Powerful Proof Anyone Can Invest for an Early Retirement - May 29, 2020

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Ironwood to Halt MD-7246 Development After Study Failure

Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.

Zacks.com headshot

Sanofi's Dupixent Gets FDA Approval for Eczema in Children

Sanofi (SNY) secures an FDA nod for Dupixent as the first biologic medicine for children aged from six to 11 years with moderate-to-severe atopic dermatitis.

argenx Up on Positive Data from Pivotal Efgartigimod Study

argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.

How Trading Your Own Retirement Can Fleece Your Financial Future - May 27, 2020

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

3 Top Dividend Stocks to Maximize Your Retirement Income - May 27, 2020

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Top Ranked Income Stocks to Buy for May 27th

Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 27th.

This is Why AbbVie (ABBV) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.